Serum SFRP4 has been shown to increase when serum sclerostin is progressively downregulated in a mouse model of CKD, suggesting a possible role of SFRP4 in maintaining Wnt inhibition despite suppression of sclerostin [107]. This evidence concerns the gene SOST and chronic kidney disease.